Compare Mercadolibre Inc (MELI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs BIO-TECHNE Corp — how do they compare? Mercadolibre Inc trades at $1,935.01 (market cap $92.49B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Mercadolibre Inc is far larger — about 8.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| MELI | TECH | |
|---|---|---|
Market Cap | $92.49B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $72.29 |
52-Week Low | $1.55K | $43.31 |
Enterprise Value | $100.14B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,820.69, down 0.51% in the last 24 hours, with a bearish technical signal. The stock shows strong revenue growth, with Q2 2026 EPS beating estimates at $9.19 versus $8.65 expected, but recent quarters have missed expectations. Valuation ratios like P/E of 49.53 are elevated, while profitability metrics include a 42.68% gross margin and 27.5% ROE. Analyst consensus is strongly bullish with a $2,020 price target, but technical indicators suggest near-term weakness.
Outlook remains positive long-term due to robust e-commerce and fintech expansion in Latin America, with revenue projected to hit $35.2B in 2026. Risks include margin pressures from heavy investments and competitive threats. The stock offers growth potential if profit trends improve, but investors face volatility from strategic spending and market sentiment shifts.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
